Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report

While immunotherapy with immune checkpoint inhibitors has achieved promising effects in advanced lung cancer treatment, it can induce some unique adverse events, known as immunotherapy-related adverse events (irAEs). Immunotherapy-related interstitial pneumonitis is one of the irAEs, and its inciden...

Full description

Bibliographic Details
Main Authors: Takuma Imakita, Kohei Fujita, Osamu Kanai, Tadashi Mio
Format: Article
Language:English
Published: Karger Publishers 2022-08-01
Series:Case Reports in Oncology
Subjects:
Online Access:https://www.karger.com/Article/FullText/525800
_version_ 1811261870481342464
author Takuma Imakita
Kohei Fujita
Osamu Kanai
Tadashi Mio
author_facet Takuma Imakita
Kohei Fujita
Osamu Kanai
Tadashi Mio
author_sort Takuma Imakita
collection DOAJ
description While immunotherapy with immune checkpoint inhibitors has achieved promising effects in advanced lung cancer treatment, it can induce some unique adverse events, known as immunotherapy-related adverse events (irAEs). Immunotherapy-related interstitial pneumonitis is one of the irAEs, and its incidence is reported as 3.5–8.3% in phase III trials of nivolumab with or without ipilimumab for advanced non-small cell lung cancer patients. However, in the real-world setting, pathology is not routinely used in the diagnostic process of interstitial pneumonitis because diagnosis is usually made using chest computed tomography (CT). Here, we report an educational case of pathologically diagnosed pulmonary lymphangitis carcinomatosa mimicking immunotherapy-related interstitial pneumonitis. The patient was diagnosed with advanced adenocarcinoma of the right lung (stage IVA) and received immunochemotherapy for 6 months. He manifested acute respiratory failure, and a chest CT scan revealed the emergence of diffuse grand-grass opacity predominantly in the left lung. Immunotherapy-induced interstitial pneumonitis was clinically suspected because the primary lesion was stable, and the level of the serum carcinoembryonic antigen decreased. However, the detection of adenocarcinoma cells in the bronchoalveolar lavage sample from the left lung confirmed the diagnosis of pulmonary lymphangitis carcinomatosa. Clinicians’ assumptions can sometimes mislead treatment methods; hence, this case draws attention to the perils of misdiagnoses.
first_indexed 2024-04-12T19:13:39Z
format Article
id doaj.art-76aebb5dd75f4971802bb52a973f570f
institution Directory Open Access Journal
issn 1662-6575
language English
last_indexed 2024-04-12T19:13:39Z
publishDate 2022-08-01
publisher Karger Publishers
record_format Article
series Case Reports in Oncology
spelling doaj.art-76aebb5dd75f4971802bb52a973f570f2022-12-22T03:19:48ZengKarger PublishersCase Reports in Oncology1662-65752022-08-0115273273710.1159/000525800525800Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case ReportTakuma ImakitaKohei Fujitahttps://orcid.org/0000-0002-6902-9085Osamu Kanaihttps://orcid.org/0000-0003-0736-3317Tadashi MioWhile immunotherapy with immune checkpoint inhibitors has achieved promising effects in advanced lung cancer treatment, it can induce some unique adverse events, known as immunotherapy-related adverse events (irAEs). Immunotherapy-related interstitial pneumonitis is one of the irAEs, and its incidence is reported as 3.5–8.3% in phase III trials of nivolumab with or without ipilimumab for advanced non-small cell lung cancer patients. However, in the real-world setting, pathology is not routinely used in the diagnostic process of interstitial pneumonitis because diagnosis is usually made using chest computed tomography (CT). Here, we report an educational case of pathologically diagnosed pulmonary lymphangitis carcinomatosa mimicking immunotherapy-related interstitial pneumonitis. The patient was diagnosed with advanced adenocarcinoma of the right lung (stage IVA) and received immunochemotherapy for 6 months. He manifested acute respiratory failure, and a chest CT scan revealed the emergence of diffuse grand-grass opacity predominantly in the left lung. Immunotherapy-induced interstitial pneumonitis was clinically suspected because the primary lesion was stable, and the level of the serum carcinoembryonic antigen decreased. However, the detection of adenocarcinoma cells in the bronchoalveolar lavage sample from the left lung confirmed the diagnosis of pulmonary lymphangitis carcinomatosa. Clinicians’ assumptions can sometimes mislead treatment methods; hence, this case draws attention to the perils of misdiagnoses.https://www.karger.com/Article/FullText/525800non-small cell lung cancerimmunotherapy-related adverse eventinterstitial pneumoniapulmonary lymphangitis carcinomatosa
spellingShingle Takuma Imakita
Kohei Fujita
Osamu Kanai
Tadashi Mio
Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
Case Reports in Oncology
non-small cell lung cancer
immunotherapy-related adverse event
interstitial pneumonia
pulmonary lymphangitis carcinomatosa
title Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
title_full Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
title_fullStr Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
title_full_unstemmed Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
title_short Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
title_sort pulmonary lymphangitis carcinomatosa mimicking immunotherapy related interstitial pneumonitis a case report
topic non-small cell lung cancer
immunotherapy-related adverse event
interstitial pneumonia
pulmonary lymphangitis carcinomatosa
url https://www.karger.com/Article/FullText/525800
work_keys_str_mv AT takumaimakita pulmonarylymphangitiscarcinomatosamimickingimmunotherapyrelatedinterstitialpneumonitisacasereport
AT koheifujita pulmonarylymphangitiscarcinomatosamimickingimmunotherapyrelatedinterstitialpneumonitisacasereport
AT osamukanai pulmonarylymphangitiscarcinomatosamimickingimmunotherapyrelatedinterstitialpneumonitisacasereport
AT tadashimio pulmonarylymphangitiscarcinomatosamimickingimmunotherapyrelatedinterstitialpneumonitisacasereport